Cdkn2a (cyclin-dependent kinase inhibitor 2A) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Cdkn2a (cyclin-dependent kinase inhibitor 2A) Rattus norvegicus
Analyze
Symbol: Cdkn2a
Name: cyclin-dependent kinase inhibitor 2A
RGD ID: 2323
Description: Predicted to enable several functions, including MDM2/MDM4 family protein binding activity; NF-kappaB binding activity; and cyclin-dependent protein serine/threonine kinase inhibitor activity. Involved in several processes, including cellular response to glucose stimulus; negative regulation of hepatocyte proliferation; and nervous system development. Located in cytoplasm and nucleus. Used to study carcinoma (multiple); endometrial cancer; pre-malignant neoplasm; rhabdomyosarcoma; and sarcomatoid mesothelioma. Biomarker of hepatocellular carcinoma; hypertension; obesity; and osteoarthritis. Human ortholog(s) of this gene implicated in several diseases, including breast cancer (multiple); carcinoma (multiple); hematologic cancer (multiple); melanoma (multiple); and pancreatic cancer (multiple). Orthologous to human CDKN2A (cyclin dependent kinase inhibitor 2A); PARTICIPATES IN altered G1/S transition pathway; G1/S transition pathway; pancreatic cancer pathway; INTERACTS WITH (+)-pilocarpine; 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dinitrotoluene.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: alternative reading frame; Arf; CDK4I; cell cycle inhibitor; cell cycle regulator; Cyclin dependent kinase inhibitor 2A (p16 inhibits CDK4); Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; INK4A; MTS1; p16; p16-INK4; p16-INK4a; p16Cdkn2a; p19ARF
RGD Orthologs
Human
Mouse
Bonobo
Dog
Pig
Alliance Genes
More Info more info ...
Allele / Splice: Cdkn2a_v1   Cdkn2a_v2  
Is Marker For: Strains:   F344/NRrrc  
Candidate Gene For: Emca11
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.25103,984,949 - 103,992,143 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl5103,984,949 - 104,003,149 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx5106,419,014 - 106,426,264 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.05108,148,629 - 108,155,881 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.05108,229,171 - 108,236,389 (-)NCBIRnor_WKY
Rnor_6.05107,823,323 - 107,832,405 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl5107,823,330 - 107,841,175 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.05111,793,603 - 111,801,220 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Rnor_5.05111,556,970 - 111,557,193 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.45108,908,749 - 108,916,380 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.15108,913,974 - 108,921,606 (-)NCBI
Celera5102,700,552 - 102,707,724 (-)NCBICelera
Cytogenetic Map5q32NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
adenocarcinoma  (ISO)
Adrenal Gland Neoplasms  (ISO)
adrenocortical carcinoma  (ISO)
B-lymphoblastic leukemia/lymphoma  (ISO)
bone disease  (ISO)
Brain Neoplasms  (ISO)
Brain Stem Neoplasms  (ISO)
breast cancer  (ISO)
Breast Neoplasms  (ISO)
Carcinogenesis  (ISO)
cervix uteri carcinoma in situ  (ISO)
cholangiocarcinoma  (ISO)
Chromosome Deletion  (ISO)
chronic myeloid leukemia  (ISO)
Colonic Neoplasms  (IEP)
Colorectal Neoplasms  (ISO)
diffuse large B-cell lymphoma  (ISO)
disease of cellular proliferation  (ISO)
dysplastic nevus syndrome  (ISO)
endometrial cancer  (IAGP)
Endometrial Neoplasms  (ISO)
esophageal carcinoma  (ISO)
Esophageal Neoplasms  (IEP,ISO)
esophagus adenocarcinoma  (ISO)
esophagus squamous cell carcinoma  (ISO)
Experimental Arthritis  (ISO)
Experimental Leukemia  (ISO)
Experimental Mammary Neoplasms  (IEP,ISO)
familial melanoma  (ISO)
Fluoride Poisoning  (ISO)
gastric adenocarcinoma  (ISO)
genetic disease  (ISO)
Genetic Translocation  (ISO)
Germ Cell and Embryonal Neoplasms  (ISO)
germinoma  (ISO)
glaucoma  (ISO)
glioblastoma  (ISO)
granulosa cell tumor  (ISO)
head and neck squamous cell carcinoma  (ISO)
hepatocellular carcinoma  (IDA,IEP,ISO)
Hereditary Neoplastic Syndromes  (ISO)
high grade glioma  (ISO)
Hyperplasia  (IEP)
hypertension  (IEP)
in situ carcinoma  (ISO)
invasive ductal carcinoma  (ISO)
Kidney Neoplasms  (ISO)
leiomyosarcoma  (ISO)
leukemia  (ISO)
Liver Neoplasms  (ISO)
lung adenocarcinoma  (ISO)
lung cancer  (ISO)
Lung Neoplasms  (IDA,ISO)
lung non-small cell carcinoma  (ISO)
lung squamous cell carcinoma  (ISO)
Lymphatic Metastasis  (ISO)
lymphoma  (ISO)
Maffucci syndrome  (ISO)
malignant mesothelioma  (ISO)
melanoma  (ISO)
melanoma and neural system tumor syndrome  (ISO)
Melanoma-Pancreatic Cancer Syndrome  (ISO)
Mesothelioma  (IAGP,ISO)
Micronuclei, Chromosome-Defective  (ISO)
Mouth Neoplasms  (ISO)
multiple myeloma  (ISO)
myelodysplastic syndrome  (ISO)
Neoplasm Invasiveness  (ISO)
Neoplasm Metastasis  (ISO)
nephroblastoma  (ISO)
Nerve Sheath Neoplasms  (ISO)
neurilemmoma  (ISO)
neuroblastoma  (ISO)
obesity  (IEP)
osteoarthritis  (IEP)
osteosarcoma  (ISO)
Ovarian Neoplasms  (ISO)
pancreatic adenocarcinoma  (ISO)
pancreatic cancer  (ISO)
pancreatic carcinoma  (ISO)
pancreatic ductal carcinoma  (ISO)
papillary renal cell carcinoma  (ISO)
papillomavirus infectious disease  (ISO)
peripheral nervous system disease  (ISO)
persistent hyperplastic primary vitreous  (ISO)
plasmacytoma  (ISO)
Poisoning  (ISO)
pre-malignant neoplasm  (IDA,ISO)
Premature Aging  (ISO)
primary cutaneous T-cell non-Hodgkin lymphoma  (ISO)
prostate adenocarcinoma  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
renal cell carcinoma  (IAGP,ISO)
retinoblastoma  (ISO)
rhabdomyosarcoma  (IDA)
sarcomatoid mesothelioma  (IAGP)
schizophrenia  (ISO)
Sezary's disease  (ISO)
skin melanoma  (ISO)
Sporadic Papillary Renal Cell Carcinoma  (ISO)
squamous cell carcinoma  (ISO)
Stomach Neoplasms  (ISO)
T-cell acute lymphoblastic leukemia  (ISO)
thymoma  (ISO)
Tongue Neoplasms  (IAGP,IEP)
transient cerebral ischemia  (ISO)
transitional cell carcinoma  (ISO)
Trisomy  (ISO)
urinary bladder cancer  (ISO)
Urogenital Neoplasms  (ISO)
uterine carcinosarcoma  (ISO)
Uterine Cervical Neoplasms  (ISO)
Vulvar Lichen Sclerosus  (ISO)
Vulvar Neoplasms  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-pilocarpine  (EXP)
(-)-epigallocatechin 3-gallate  (ISO)
(S)-nicotine  (ISO)
(Z)-3-butylidenephthalide  (ISO)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
17beta-estradiol  (ISO)
17beta-hydroxy-17-methylestra-4,9,11-trien-3-one  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-dinitrotoluene  (EXP)
2-acetamidofluorene  (EXP)
3-chloropropane-1,2-diol  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (ISO)
4-hydroxyphenyl retinamide  (ISO)
4-phenylbutyric acid  (ISO)
4-vinylcyclohexene dioxide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (EXP,ISO)
5-fluorouracil  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (ISO)
aflatoxin B1  (ISO)
agomelatine  (EXP)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
alpha-D-galactose  (EXP)
ammonium chloride  (EXP)
amosite asbestos  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
aristolochic acid A  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (EXP,ISO)
asbestos  (ISO)
belinostat  (ISO)
benzene  (ISO)
benzo[a]pyrene  (EXP,ISO)
benzo[b]fluoranthene  (ISO)
beryllium atom  (EXP)
beryllium dihydride  (EXP)
beryllium sulfate  (ISO)
beryllium(0)  (EXP)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
BMS-754807  (ISO)
busulfan  (ISO)
Butylbenzyl phthalate  (ISO)
butyric acid  (ISO)
C60 fullerene  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
calcium dichloride  (EXP)
cannabidiol  (EXP,ISO)
capecitabine  (ISO)
capsaicin  (ISO)
carbon nanotube  (ISO)
carmustine  (ISO)
casticin  (ISO)
chloramphenicol  (ISO)
chloroethene  (ISO)
chromium atom  (ISO)
chromium(6+)  (EXP,ISO)
chymostatin  (ISO)
cisplatin  (ISO)
clofibric acid  (EXP)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
cordycepin  (EXP)
corticosterone  (EXP)
crocidolite asbestos  (ISO)
curcumin  (ISO)
cycloheximide  (ISO)
D-glucose  (ISO)
daunorubicin  (ISO)
DDT  (EXP)
dehydroepiandrosterone  (EXP)
Deoxycorticosterone acetate  (EXP)
Diacetoxyscirpenol  (ISO)
diarsenic trioxide  (EXP,ISO)
dibutyl phthalate  (ISO)
dichloroacetic acid  (ISO)
dichromic acid  (ISO)
dichromium trioxide  (ISO)
diethyl phthalate  (ISO)
diisobutyl phthalate  (ISO)
diisononyl phthalate  (ISO)
dimethylarsinic acid  (EXP,ISO)
dioscin  (ISO)
dioxygen  (ISO)
disodium selenite  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
entinostat  (EXP)
ethanol  (ISO)
etoposide  (EXP,ISO)
farrerol  (ISO)
fenbendazole  (EXP)
ferric oxide  (ISO)
ferrostatin-1  (EXP)
fluoxetine  (ISO)
folic acid  (ISO)
fumonisin B1  (ISO)
furan  (EXP)
galactose  (EXP)
gamma-tocopherol  (ISO)
glucaric acid  (ISO)
glucose  (ISO)
glycidol  (EXP)
glycine betaine  (EXP)
glyphosate  (ISO)
GW 3965  (ISO)
harmine  (ISO)
hexachlorobenzene  (EXP)
hydralazine  (EXP,ISO)
hydrochlorothiazide  (EXP)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
hydroxyurea  (ISO)
imidacloprid  (ISO)
irbesartan  (ISO)
irinotecan  (ISO)
isocyanates  (ISO)
ivermectin  (ISO)
L-ascorbic acid  (EXP)
lead diacetate  (ISO)
lidocaine  (ISO)
linalool  (ISO)
lithium chloride  (ISO)
losartan  (ISO)
LY294002  (ISO)
maneb  (EXP)
masoprocol  (ISO)
Mecamylamine  (ISO)
melatonin  (EXP)
menadione  (ISO)
menaquinone  (ISO)
mercury dibromide  (ISO)
methimazole  (EXP)
methoxyacetic acid  (ISO)
methoxychlor  (ISO)
methylmercury chloride  (EXP,ISO)
methylseleninic acid  (ISO)
microcystin RR  (ISO)
microcystin-LR  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monobenzyl phthalate  (ISO)
Monobutylphthalate  (ISO)
monoethyl phthalate  (ISO)
monosodium L-glutamate  (EXP,ISO)
myo-inositol hexakisphosphate  (ISO)
N-acetyl-L-cysteine  (ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-ethyl-N-nitrosourea  (ISO)
N-methyl-4-phenylpyridinium  (EXP,ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
nickel dichloride  (EXP)
nickel subsulfide  (EXP)
nicotinamide  (ISO)
nicotine  (ISO)
nitrogen dioxide  (EXP)
O-methyleugenol  (EXP)
ochratoxin A  (ISO)
oxaliplatin  (ISO)
ozone  (ISO)
p-menthan-3-ol  (ISO)
palbociclib  (ISO)
paracetamol  (ISO)
paraquat  (EXP)
parathion  (ISO)
perfluorooctanoic acid  (ISO)
phenethyl caffeate  (EXP)
phenobarbital  (ISO)
phenylmercury acetate  (ISO)
PhIP  (EXP)
phorbol 13-acetate 12-myristate  (ISO)
pirinixic acid  (ISO)
piroxicam  (EXP)
potassium dichromate  (ISO)
prednisone  (ISO)
proanthocyanidin  (EXP)
procainamide  (ISO)
promethazine  (EXP)
pterostilbene  (ISO)
quercetin  (EXP,ISO)
quinoline  (ISO)
radon atom  (ISO)
radon(0)  (ISO)
reserpine  (EXP)
resveratrol  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
salubrinal  (EXP)
SB 203580  (ISO)
SB 431542  (ISO)
serpentine asbestos  (EXP)
silver(1+) nitrate  (ISO)
simvastatin  (EXP)
sodium arsenate  (ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (ISO)
sodium fluoride  (ISO)
spironolactone  (EXP)
stavudine  (ISO)
streptozocin  (ISO)
sulforaphane  (ISO)
sulfur dioxide  (EXP)
sulindac  (EXP)
T-2 toxin  (EXP)
terephthalic acid  (EXP)
tetrachloromethane  (ISO)
thioacetamide  (EXP)
thioridazine  (ISO)
titanium dioxide  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
urethane  (ISO)
valproic acid  (ISO)
vincristine  (ISO)
vinorelbine  (ISO)
wogonin  (ISO)
zearalenone  (ISO)
zidovudine  (ISO)
zinc pyrithione  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
activation of cysteine-type endopeptidase activity involved in apoptotic process  (ISO)
aging  (IEP,ISO)
amyloid fibril formation  (ISO)
apoptotic mitochondrial changes  (ISO)
apoptotic process  (IEA)
apoptotic process involved in mammary gland involution  (ISO)
autophagy of mitochondrion  (ISO)
cellular response to glucose stimulus  (IEP)
cellular response to hydrogen peroxide  (ISO)
cellular senescence  (ISO)
cerebellum development  (IEP)
epidermis development  (ISO)
glucose homeostasis  (ISO)
mammary gland epithelial cell proliferation  (ISO)
mitochondrial depolarization  (ISO)
negative regulation of B cell proliferation  (ISO)
negative regulation of cell cycle  (ISO)
negative regulation of cell growth  (ISO)
negative regulation of cell population proliferation  (IEA,ISO)
negative regulation of cell-matrix adhesion  (ISO)
negative regulation of cyclin-dependent protein serine/threonine kinase activity  (ISO)
negative regulation of DNA-templated transcription  (ISO)
negative regulation of hepatocyte proliferation  (IMP)
negative regulation of immature T cell proliferation in thymus  (ISO)
negative regulation of mammary gland epithelial cell proliferation  (ISO)
negative regulation of NF-kappaB transcription factor activity  (ISO)
negative regulation of phosphorylation  (ISO)
negative regulation of protein binding  (ISO)
negative regulation of protein kinase activity  (ISO)
negative regulation of protein neddylation  (ISO)
negative regulation of proteolysis involved in protein catabolic process  (ISO)
negative regulation of ubiquitin protein ligase activity  (ISO)
negative regulation of ubiquitin-dependent protein catabolic process  (ISO)
negative regulation of ubiquitin-protein transferase activity  (ISO)
neurogenesis  (IEP)
obsolete cell aging  (ISO)
positive regulation of apoptotic process  (IMP,ISO,ISS)
positive regulation of apoptotic process involved in mammary gland involution  (ISO)
positive regulation of DNA damage response, signal transduction by p53 class mediator  (ISO)
positive regulation of DNA-binding transcription factor activity  (ISO)
positive regulation of DNA-templated transcription  (ISO)
positive regulation of gene expression  (ISO)
positive regulation of macrophage apoptotic process  (ISO)
positive regulation of protein localization to nucleus  (ISO)
positive regulation of protein sumoylation  (ISO)
positive regulation of signal transduction by p53 class mediator  (ISO)
positive regulation of smooth muscle cell apoptotic process  (ISO)
positive regulation of transcription by RNA polymerase II  (ISO)
protein destabilization  (ISO)
protein K63-linked ubiquitination  (ISO,ISS)
protein polyubiquitination  (ISO,ISS)
protein stabilization  (ISO)
protein sumoylation  (IEA)
Ras protein signal transduction  (ISO)
regulation of apoptotic DNA fragmentation  (ISO)
regulation of cell cycle  (IEA,ISO)
regulation of cyclin-dependent protein serine/threonine kinase activity  (ISO)
regulation of DNA-binding transcription factor activity  (ISO)
regulation of G1/S transition of mitotic cell cycle  (ISO)
regulation of G2/M transition of mitotic cell cycle  (ISO)
regulation of gene expression  (ISO)
regulation of nucleocytoplasmic transport  (ISO)
regulation of protein export from nucleus  (ISO)
regulation of protein stability  (ISO)
regulation of protein targeting to mitochondrion  (ISO)
replicative senescence  (ISO)
response to caloric restriction  (IEP)
response to fatty acid  (IEP)
response to organic cyclic compound  (IDA)
response to organic substance  (IEP)
response to organonitrogen compound  (IDA)
response to salt stress  (IEP)
response to xenobiotic stimulus  (IDA,IEP)
rRNA processing  (IEA)
rRNA transcription  (ISO)
somatic stem cell division  (ISO)
somatic stem cell population maintenance  (ISO)

Cellular Component

Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
# Reference Title Reference Citation
1. Rearrangement and allelic imbalance on chromosome 5 leads to homozygous deletions in the CDKN2A/2B tumor suppressor gene region in rat endometrial cancer. Adamovic T, etal., Cancer Genet Cytogenet. 2008 Jul;184(1):9-21.
2. Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors. Arcellana-Panlilio MY, etal., Genes Chromosomes Cancer. 2002 Oct;35(2):176-81.
3. Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. Askari M, etal., Mol Biol Rep. 2013 Aug;40(8):4921-8. doi: 10.1007/s11033-013-2592-5. Epub 2013 May 28.
4. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Bagnyukova TV, etal., Carcinogenesis. 2008 Jan 19;.
5. p16 hypermethylation during gastric carcinogenesis of Wistar rats by N-methyl-N'-nitro-N-nitrosoguanidine. Bai H, etal., Mutat Res. 2003 Feb 5;535(1):73-8.
6. Aberrant CpG island methylation of the p16(INK4a) and estrogen receptor genes in rat lung tumors induced by particulate carcinogens. Belinsky SA, etal., Carcinogenesis 2002 Feb;23(2):335-9.
7. Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Benevolo M, etal., Mod Pathol. 2006 Mar;19(3):384-91.
8. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. Borg A, etal., J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6.
9. Expression of the cell cycle regulators p53, p21(WAF1/CIP1) and p16(INK4a) in human endometrial adenocarcinoma. Buchynska LG and Nesina IP, Exp Oncol. 2006 Jun;28(2):152-5.
10. p14ARF and p16INK4A, two products of the same gene, are differently expressed in cervical intraepithelial neoplasia. Bulten J, etal., Gynecol Oncol. 2006 Jun;101(3):487-94. Epub 2006 Jan 9.
11. Role of INK4a locus in normal eye development and cataract genesis. Cheong C, etal., Mech Ageing Dev. 2006 Jul;127(7):633-8. Epub 2006 Apr 18.
12. Ocular expression and distribution of products of the POAG-associated chromosome 9p21 gene region. Chidlow G, etal., PLoS One. 2013 Sep 19;8(9):e75067. doi: 10.1371/journal.pone.0075067. eCollection 2013.
13. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. Chien WW, etal., Leuk Res. 2015 Apr;39(4):453-61. doi: 10.1016/j.leukres.2015.01.008. Epub 2015 Jan 25.
14. Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia. Cividin M, etal., Leuk Res. 2006 Oct;30(10):1273-8. Epub 2006 Mar 14.
15. Prevalence of mucosal and cutaneous human papillomaviruses in different histologic subtypes of vulvar carcinoma. de Koning MN, etal., Mod Pathol. 2008 Jan 11;.
16. Novel CDKN2A mutation detected in Spanish melanoma pedigree. de Torre C and Martinez-Escribano J, Exp Dermatol. 2010 Aug;19(8):e333-5. doi: 10.1111/j.1600-0625.2009.01048.x.
17. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. Debies MT, etal., J Clin Invest. 2008 Jan;118(1):51-63.
18. A common variant of CDKN2A (p16) predisposes to breast cancer. Debniak T, etal., J Med Genet. 2005 Oct;42(10):763-5. Epub 2005 May 6.
19. Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells. Diaz-Rodriguez E, etal., Oncogene. 2012 Jun 7;31(23):2824-35. doi: 10.1038/onc.2011.458. Epub 2011 Oct 24.
20. Population-based prevalence of CDKN2A mutations in Utah melanoma families. Eliason MJ, etal., J Invest Dermatol. 2006 Mar;126(3):660-6.
21. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Faderl S, etal., Cancer. 2000 Nov 1;89(9):1976-82.
22. p16INK4A tumor suppressor gene expression and CD3epsilon deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis. Fasseu M, etal., Blood. 2007 Oct 1;110(7):2610-9. Epub 2007 May 16.
23. Immunohistochemical expression of p16(INK4A) in normal uterine cervix, nonneoplastic epithelial lesions, and low-grade squamous intraepithelial lesions. Focchi GR, etal., J Low Genit Tract Dis. 2007 Apr;11(2):98-104.
24. Early deregulation of the the p16ink4a-cyclin D1/cyclin-dependent kinase 4-retinoblastoma pathway in cell proliferation-driven esophageal tumorigenesis in zinc-deficient rats. Fong LY, etal., Cancer Res. 2000 Aug 15;60(16):4589-95.
25. Reduced expression of INK4a/ARF genes in stem-like sphere cells from rat sarcomas. Fujii H, etal., Biochem Biophys Res Commun. 2007 Oct 26;362(3):773-8. Epub 2007 Aug 22.
26. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants. Gannon BR, etal., Int J Gynecol Pathol. 2008 Jan;27(1):68-73.
27. High frequency of aberrant p16(INK4A) expression in human breast cancer. Geradts J and Wilson PA, Am J Pathol. 1996 Jul;149(1):15-20.
28. Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Guillerm G, etal., Haematologica. 2003 Apr;88(4):476-8.
29. Role of p16(INK4a) in the inhibition of DNA synthesis stimulated by HGF or EGF in primary cultured rat hepatocytes. Harashima M, etal., Biomed Res. 2013;34(5):269-73.
30. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds. Hashemi J, etal., Melanoma Res. 1999 Feb;9(1):21-30.
31. Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-lymphoblastic leukemia. Hauer J, etal., Blood. 2011 Jul 21;118(3):544-53. doi: 10.1182/blood-2010-09-305383. Epub 2011 May 26.
32. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. Heidenreich A, etal., J Urol. 1998 May;159(5):1725-30.
33. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Herman JG, etal., Cancer Res. 1996 Feb 15;56(4):722-7.
34. Specific allelic loss of p16 (INK4A) tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Hiroyasu M, etal., Am J Pathol 2002 Feb;160(2):419-24.
35. Frequent mutation of p16(CDKN2A) exon 1 during rat tongue carcinogenesis induced by 4-nitroquinoline-1-oxide. Hong Y, etal., Mol Carcinog. 2007 Feb;46(2):85-90.
36. p16(CDKN2A) expression during rat tongue carcinogenesis induced by 4-nitroquinoline-1-oxide. Hong Y, etal., Oral Oncol. 2009 Jul;45(7):640-4. doi: 10.1016/j.oraloncology.2008.06.007. Epub 2008 Sep 18.
37. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Hu Q, etal., Lab Invest. 2010 Mar;90(3):360-73. doi: 10.1038/labinvest.2009.140. Epub 2010 Jan 11.
38. Expression of p16(INK4A) induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest. Hung KS, etal., Biochem Biophys Res Commun. 2000 Mar 24;269(3):718-25.
39. DNA copy number aberrations and disruption of the p16Ink4a/Rb pathway in radiation-induced and spontaneous rat mammary carcinomas. Iizuka D, etal., Radiat Res. 2010 Aug;174(2):206-15. doi: 10.1667/RR2006.1.
40. Gene Data File Integration of LocusLink data, October 12, 2001
41. Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. Ishikawa A, etal., Hum Pathol. 2004 Dec;35(12):1505-14.
42. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Jones S, etal., Science. 2008 Sep 26;321(5897):1801-6. Epub 2008 Sep 4.
43. Methylation of p16INK4a is a non-rare event in cervical intraepithelial neoplasia. Kang S, etal., Diagn Mol Pathol. 2006 Jun;15(2):74-82.
44. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Kannan K, etal., Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1221-5. Epub 2003 Jan 21.
45. Homozygous deletions of the INK4a/ARF locus in renal cell cancer. Kasahara T, etal., Anticancer Res. 2006 Nov-Dec;26(6B):4299-305.
46. Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. Katchanov J, etal., J Neurosci. 2001 Jul 15;21(14):5045-53.
47. Molecular targeting of neuroblastoma with a novel p16INK4a transporter system. Kawaguchi T, etal., Int J Oncol. 2014 Jun;44(6):1879-85. doi: 10.3892/ijo.2014.2372. Epub 2014 Apr 7.
48. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Kawamoto K, etal., Biochem Biophys Res Commun. 2006 Jan 20;339(3):790-6. Epub 2005 Nov 22.
49. Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas. Kiss NB, etal., Endocr Relat Cancer. 2008 Jun;15(2):609-21. doi: 10.1677/ERC-07-0285.
50. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Kommoss S, etal., Br J Cancer. 2007 Jan 29;96(2):306-13.
51. The effect of phenobarbital on the methylation level of the p16 promoter region in rat liver. Kostka G, etal., Toxicology. 2007 Sep 24;239(1-2):127-35. Epub 2007 Jul 12.
52. Epigenetic changes in the rat livers induced by pyrazinamide treatment. Kovalenko VM, etal., Toxicol Appl Pharmacol. 2007 Dec 15;225(3):293-9. Epub 2007 Aug 23.
53. Mts1 protein expression in the central nervous system after injury. Kozlova EN and Lukanidin E, Glia 2002 Mar 15;37(4):337-48.
54. Ink4a/Arf expression is a biomarker of aging. Krishnamurthy J, etal., J Clin Invest 2004 Nov;114(9):1299-307.
55. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Labuhn M, etal., Oncogene. 2001 Mar 1;20(9):1103-9.
56. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Laharanne E, etal., Mod Pathol. 2010 Apr;23(4):547-58. doi: 10.1038/modpathol.2009.196. Epub 2010 Jan 29.
57. p16INK4A-silencing augments DNA damage-induced apoptosis in cervical cancer cells. Lau WM, etal., Oncogene. 2007 Sep 6;26(41):6050-60. Epub 2007 Mar 19.
58. Dynamic changes in DNA methylation during multistep rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine. Liu WB, etal., Toxicol Lett. 2009 Aug 25;189(1):5-13. doi: 10.1016/j.toxlet.2009.04.022. Epub 2009 May 3.
59. Effects of calcium sensitizer OR-1986 on a cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats. Louhelainen M, etal., J Physiol Pharmacol. 2009 Sep;60(3):41-7.
60. [Loss of heterozygosity in the 9p21 region as an inactivation mechanism of the p16 suppressor gene]. Maestro de las Casas ML, etal., Arch Esp Urol. 2000 Sep;53(7):603-9.
61. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Maloney KW, etal., Blood. 1999 Apr 1;93(7):2380-5.
62. Lack of ETV6 (TEL) gene rearrangements or p16INK4A/p15INK4B homozygous gene deletions in infant acute lymphoblastic leukemia. Maloney KW, etal., Leukemia. 1997 Jul;11(7):979-83.
63. Ribosomal biogenesis induction by high glucose requires activation of upstream binding factor in kidney glomerular epithelial cells. Mariappan MM, etal., Am J Physiol Renal Physiol. 2011 Jan;300(1):F219-30. doi: 10.1152/ajprenal.00207.2010. Epub 2010 Oct 13.
64. Carcinogen exposure and epigenetic silencing in bladder cancer. Marsit CJ, etal., Ann N Y Acad Sci. 2006 Sep;1076:810-21.
65. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
66. P16(INK4a) immunocytochemistry in liquid-based cytology samples in equivocal Pap smears: added value in management of women with equivocal Pap smear. Monsonego J, etal., Acta Cytol. 2007 Sep-Oct;51(5):755-66.
67. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Morey SR, etal., Cancer Res. 2006 Dec 15;66(24):11659-67.
68. Coordinated control of self-renewal and differentiation of neural stem cells by Myc and the p19ARF-p53 pathway. Nagao M, etal., J Cell Biol. 2008 Dec 29;183(7):1243-57. doi: 10.1083/jcb.200807130.
69. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. Nakao M, etal., Leukemia. 1996 Feb;10(2):249-54.
70. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours. Natrajan R, etal., J Clin Pathol. 2008 Jan;61(1):95-102. Epub 2007 Mar 16.
71. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
72. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Nielsen GP, etal., Am J Pathol 1999 Dec;155(6):1879-84.
73. Immunohistochemical expression of p16 and p53 in vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva. Nogueira MC, etal., Pathol Oncol Res. 2006;12(3):153-7. Epub 2006 Sep 23.
74. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. O'Neill CJ, etal., Histopathology. 2007 May;50(6):773-9.
75. Selective loss of resistant alleles at p15(INK4B) and p16(INK4A) genes in chemically-induced rat tongue cancers. Ogawa K, etal., Oral Oncol. 2006 Mar 7;.
76. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
77. Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma. Park TJ, etal., Mol Carcinog. 2001 Mar;30(3):138-50.
78. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Pascale RM, etal., Hepatology. 2005 Dec;42(6):1310-9.
79. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
80. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. Platz A, etal., J Natl Cancer Inst. 1997 May 21;89(10):697-702.
81. De novo methylation of the p16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats. Pogribny IP and James SJ, Cancer Lett. 2002 Dec 10;187(1-2):69-75.
82. GOA pipeline RGD automated data pipeline
83. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
84. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
85. Comprehensive gene review and curation RGD comprehensive gene curation
86. Loss of p16 in recurrent malignant mixed mullerian tumors of the uterus. Robinson-Bennett B, etal., Int J Gynecol Cancer. 2006 May-Jun;16(3):1354-7.
87. Epigenetic alterations of p15(INK4B) and p16(INK4A) genes in pediatric primary myelodysplastic syndrome. Rodrigues EF, etal., Leuk Lymphoma. 2010 Oct;51(10):1887-94. doi: 10.3109/10428194.2010.505820.
88. The INK4a /ARF locus: role in cell cycle control for renal cell epithelial tumor growth after the Chernobyl accident. Romanenko A, etal., Virchows Arch. 2004 Sep;445(3):298-304. Epub 2004 Jul 1.
89. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Shank-Calvo JA, etal., Oncogene. 2006 May 18;25(21):3023-31.
90. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Sharma G, etal., Life Sci. 2007 Apr 24;80(20):1873-81. Epub 2007 Feb 27.
91. The Pezcoller lecture: cancer cell cycles revisited. Sherr CJ Cancer Res. 2000 Jul 15;60(14):3689-95.
92. INK4a-ARF mutations in skin carcinomas from UV irradiated hairless mice. Soufir N, etal., Mol Carcinog. 2004 Apr;39(4):195-8.
93. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Sugimoto M, etal., Mol Cell 2003 Feb;11(2):415-24.
94. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Swafford DS, etal., Mol Cell Biol 1997 Mar;17(3):1366-74.
95. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Taniguchi K, etal., Nat Med. 1999 Jul;5(7):760-7.
96. Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. Tao L, etal., Carcinogenesis. 2002 Sep;23(9):1447-54.
97. Coexistence of copy number changes of different genes (INK4A, erbB-1, erbB-2, CMYC, CCND1 and ZNF217) in urothelial tumors. Toncheva D and Zaharieva B, Tumour Biol. 2005 Mar-Apr;26(2):88-93. Epub 2005 May 13.
98. Accelerated aging phenotype in mice with conditional deficiency for mitochondrial superoxide dismutase in the connective tissue. Treiber N, etal., Aging Cell. 2011 Apr;10(2):239-54. doi: 10.1111/j.1474-9726.2010.00658.x. Epub 2010 Dec 29.
99. Different p16INK4a and p14ARF expression patterns in acute myeloid leukaemia and normal blood leukocytes. Tschan MP, etal., Leuk Lymphoma. 2001 Sep-Oct;42(5):1077-87.
100. Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia. Volanakis EJ, etal., Blood. 2009 Nov 12;114(20):4451-9. doi: 10.1182/blood-2009-07-233346. Epub 2009 Sep 16.
101. Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia. Volanakis EJ, etal., Exp Hematol. 2013 Apr;41(4):377-86. doi: 10.1016/j.exphem.2012.11.006. Epub 2012 Nov 23.
102. Effect of Colla corii asini (E'jiao) on D-galactose induced aging mice. Wang D, etal., Biol Pharm Bull. 2012;35(12):2128-32.
103. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ. Wang TJ, etal., Biochem Biophys Res Commun. 2001 Sep 14;287(1):173-80.
104. Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development. Watanabe G, etal., Brain Res Dev Brain Res. 1998 Jun 15;108(1-2):77-87.
105. Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Westhoff JH, etal., Hypertension. 2008 Jul;52(1):123-9. Epub 2008 May 26.
106. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Wiley A, etal., Cancer. 2006 Jul 15;107(2):299-308.
107. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Williams RT, etal., Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93. Epub 2006 Apr 17.
108. Duhuo Jisheng Decoction promotes chondrocyte proliferation through accelerated G1/S transition in osteoarthritis. Wu G, etal., Int J Mol Med. 2013 Nov;32(5):1001-10. doi: 10.3892/ijmm.2013.1481. Epub 2013 Sep 4.
109. Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Xu H, etal., Nat Commun. 2015 Jun 24;6:7553. doi: 10.1038/ncomms8553.
110. [Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma] Yao Q, etal., Zhonghua Nan Ke Xue. 2006 Jan;12(1):28-31.
111. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Yin M, etal., Hum Pathol. 2008 Apr;39(4):527-35. Epub 2008 Jan 30.
112. Modulation of expression of p16 and her2 in rat breast tissues of mammary hyperplasia model by external use of rupifang extract. Zhang G, etal., J Tradit Chin Med. 2012 Dec;32(4):651-6.
113. Methylation of RAR-beta2, RASSF1A, and CDKN2A genes induced by nickel subsulfide and nickel-carcinogenesis in rats. Zhang J, etal., Biomed Environ Sci. 2011 Apr;24(2):163-71. doi: 10.3967/0895-3988.2011.02.011.
114. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Zhang SL, etal., Mol Cell Biol. 2001 Jan;21(1):310-8.
115. Hepatic cellular senescence pathway genes are induced through histone modifications in a diet-induced obese rat model. Zhang X, etal., Am J Physiol Gastrointest Liver Physiol. 2012 Mar 1;302(5):G558-64. doi: 10.1152/ajpgi.00032.2011. Epub 2011 Dec 22.
116. p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Zhang Y, etal., Cancer. 2011 Mar 15;117(6):1227-35. doi: 10.1002/cncr.25605. Epub 2010 Nov 8.
117. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Zhang Z, etal., Mod Pathol. 2006 Oct;19(10):1339-43. Epub 2006 Jun 23.
118. Histone deacetylase 3 (HDAC3) participates in the transcriptional repression of the p16 (INK4a) gene in mammary gland of the female rat offspring exposed to an early-life high-fat diet. Zheng S, etal., Epigenetics. 2012 Feb;7(2):183-90. doi: 10.4161/epi.7.2.18972.
Additional References at PubMed
PMID:7603984   PMID:7651726   PMID:7739547   PMID:8259215   PMID:9054499   PMID:9529249   PMID:9878046   PMID:10205165   PMID:10208428   PMID:10353611   PMID:10360174   PMID:11438662  
PMID:11551927   PMID:11718560   PMID:11748239   PMID:11800646   PMID:12082630   PMID:12130539   PMID:12154087   PMID:12417039   PMID:12630860   PMID:14720514   PMID:14966292   PMID:15105443  
PMID:15144691   PMID:15149599   PMID:15201967   PMID:15355988   PMID:15485902   PMID:15567177   PMID:15582998   PMID:15964995   PMID:15989966   PMID:16173922   PMID:16199867   PMID:16243918  
PMID:16760664   PMID:16901784   PMID:17110379   PMID:17310983   PMID:17569660   PMID:18019407   PMID:18305112   PMID:18396777   PMID:18560357   PMID:18625840   PMID:18656278   PMID:18704299  
PMID:18809582   PMID:18818403   PMID:18957199   PMID:19057511   PMID:19255859   PMID:19642983   PMID:20381282   PMID:20808772   PMID:20934317   PMID:21911473   PMID:22094112   PMID:22320862  
PMID:22681889   PMID:22729085   PMID:22873822   PMID:22952318   PMID:22984612   PMID:23277542   PMID:24616519   PMID:25217637   PMID:25865695   PMID:27323397   PMID:29166374   PMID:31687322  
PMID:32080953   PMID:33010296   PMID:33941588   PMID:34334511  


Genomics

Comparative Map Data
Cdkn2a
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.25103,984,949 - 103,992,143 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl5103,984,949 - 104,003,149 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx5106,419,014 - 106,426,264 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.05108,148,629 - 108,155,881 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.05108,229,171 - 108,236,389 (-)NCBIRnor_WKY
Rnor_6.05107,823,323 - 107,832,405 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl5107,823,330 - 107,841,175 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.05111,793,603 - 111,801,220 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Rnor_5.05111,556,970 - 111,557,193 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.45108,908,749 - 108,916,380 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.15108,913,974 - 108,921,606 (-)NCBI
Celera5102,700,552 - 102,707,724 (-)NCBICelera
Cytogenetic Map5q32NCBI
CDKN2A
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38921,967,752 - 21,995,324 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl921,967,752 - 21,995,301 (-)EnsemblGRCh38hg38GRCh38
GRCh37921,967,751 - 21,995,323 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36921,957,751 - 21,984,490 (-)NCBINCBI36Build 36hg18NCBI36
Build 34921,957,751 - 21,984,490NCBI
Celera921,906,103 - 21,932,858 (-)NCBICelera
Cytogenetic Map9p21.3NCBI
HuRef921,930,969 - 21,957,759 (-)NCBIHuRef
CHM1_1921,967,646 - 21,994,319 (-)NCBICHM1_1
T2T-CHM13v2.0921,982,052 - 22,009,697 (-)NCBIT2T-CHM13v2.0
Cdkn2a
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39489,192,710 - 89,212,856 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl489,192,708 - 89,212,890 (-)EnsemblGRCm39 Ensembl
GRCm38489,274,473 - 89,294,619 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl489,274,471 - 89,294,653 (-)EnsemblGRCm38mm10GRCm38
MGSCv37488,920,377 - 88,940,523 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36488,745,868 - 88,765,796 (-)NCBIMGSCv36mm8
Celera487,760,902 - 87,780,610 (-)NCBICelera
Cytogenetic Map4C4NCBI
cM Map442.15NCBI
CDKN2A
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.1922,420,748 - 22,447,243 (-)NCBIpanpan1.1PanPan1.1panPan2
Mhudiblu_PPA_v0921,803,862 - 21,831,322 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
CDKN2A
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11141,223,316 - 41,226,056 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1141,223,315 - 41,264,379 (-)EnsemblCanFam3.1canFam3CanFam3.1
UMICH_Zoey_3.11140,835,885 - 40,865,099 (-)NCBIUMICH_Zoey_3.1
UU_Cfam_GSD_1.01141,337,054 - 41,366,301 (-)NCBIUU_Cfam_GSD_1.0
CDKN2A
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1200,792,469 - 200,798,854 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11200,774,496 - 200,799,149 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21223,989,828 - 223,992,651 (-)NCBISscrofa10.2Sscrofa10.2susScr3

Variants

.
Variants in Cdkn2a
43 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:62
Count of miRNA genes:60
Interacting mature miRNAs:61
Transcripts:ENSRNOT00000066011
Prediction methods:Microtar, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
70212Niddm25Non-insulin dependent diabetes mellitus QTL 253.54blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)51131345958Rat
1576314Eutr1Estrogen induced uterine response QTL 1uterus integrity trait (VT:0010575)pyometritis severity score (CMO:0002009)52138965166875058Rat
634305Mamtr1Mammary tumor resistance QTL 10.0001mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)512789751113558310Rat
2290448Scl54Serum cholesterol level QTL 542.93blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)531663789131345958Rat
1576317Eutr2Estrogen induced uterine response QTL 20.01uterus integrity trait (VT:0010575)pyometritis severity score (CMO:0002009)534730116104251008Rat
2316959Gluco59Glucose level QTL 594.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)534944474113558310Rat
1641912Alcrsp18Alcohol response QTL 18response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)535189153141643988Rat
1549845Scl44Serum cholesterol level QTL 446blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)540128307148607290Rat
1331801Rf33Renal function QTL 334.149kidney blood vessel physiology trait (VT:0100012)absolute change in renal vascular resistance (CMO:0001900)543726656129132602Rat
1578766Tcas11Tongue tumor susceptibility QTL 114.12tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)546711509161317411Rat
1576312Emca8Estrogen-induced mammary cancer QTL 84.1mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)550328551141643988Rat
70189Mcs5Mammary carcinoma susceptibility QTL 510.51mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)555805606132207589Rat
1358895Bp254Blood pressure QTL 2543.60.0003arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)558829236128034027Rat
61426Scl2Serum cholesterol level QTL 27.30.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)559793399143070159Rat
2316957Pur21Proteinuria QTL 216.2urine protein amount (VT:0005160)urine protein level (CMO:0000591)559793528113558156Rat
61393Bp7Blood pressure QTL 74.50.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)560293434161481680Rat
2290005Mcs24Mammary carcinoma susceptibility QTL 24mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)564719390109719390Rat
2306971Anxrr21Anxiety related response QTL 219.47fear/anxiety-related behavior trait (VT:1000241)number of entries into a discrete space in an experimental apparatus (CMO:0000960)566174080124160948Rat
2312671Scl64Serum cholesterol level QTL 640.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)568984307104251008Rat
61380Edpm5Estrogen-dependent pituitary mass QTL 54.50.92pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)568984307104251008Rat
1357396Bw44Body weight QTL 444.19body mass (VT:0001259)body weight (CMO:0000012)568984307104251008Rat
1357402Bw46Body weight QTL 464.47body mass (VT:0001259)body mass index (BMI) (CMO:0000105)568984307104251008Rat
2302381Bw84Body weight QTL 844.47body mass (VT:0001259)body mass index (BMI) (CMO:0000105)568984307104251008Rat
1354598Srn6Serum renin concentration QTL 63.8blood renin amount (VT:0003349)plasma renin activity level (CMO:0000116)569540295151018848Rat
1298070Scl18Serum cholesterol level QTL 183.7blood LDL cholesterol amount (VT:0000181)calculated plasma low density lipoprotein cholesterol level (CMO:0001245)579584860124584860Rat
1598846Bp293Blood pressure QTL 2933.9arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)579584860124584860Rat
1598859Cm66Cardiac mass QTL 662heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)579584860124584860Rat
1302790Scl20Serum cholesterol level QTL 206.40.0001blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)582394392166664054Rat
1298086Bp156Blood pressure QTL 156arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)584132602129132602Rat
7411601Foco12Food consumption QTL 1219.70.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)587468046132468046Rat
7411564Bw135Body weight QTL 1350.001body mass (VT:0001259)body weight gain (CMO:0000420)587468046132468046Rat
7411582Foco3Food consumption QTL 37.50.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)587468046132468046Rat
6903316Bw113Body weight QTL 11320.0103body mass (VT:0001259)body weight (CMO:0000012)587765973132765973Rat
1358889Bp261Blood pressure QTL 2612.86arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)590067849128034027Rat
1358909Kidm25Kidney mass QTL 251.87kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)590067849128034027Rat
631527Tls1T-lymphoma susceptibility QTL 100.001thymus integrity trait (VT:0010555)post-insult time to onset of T-cell lymphoma (CMO:0001907)590450144135450144Rat
61452Ciaa5CIA Autoantibody QTL 53.5blood autoantibody amount (VT:0003725)calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281)594858972143070159Rat
1331796Thshl2Thyroid stimulating hormone level QTL 22.3blood thyroid-stimulating hormone amount (VT:0005119)serum thyroid stimulating hormone level (CMO:0001248)597059760147465714Rat
2317753Glom24Glomerulus QTL 243.1kidney glomerulus integrity trait (VT:0010546)kidney sclerotic glomeruli count to total glomeruli count ratio (CMO:0001269)597570330136479578Rat
1582212Livw2Liver weight QTL 23.50.0004liver mass (VT:0003402)liver weight to body weight ratio (CMO:0000633)599016066119085810Rat
1358187Emca1Estrogen-induced mammary cancer QTL 14.4mammary gland integrity trait (VT:0010552)post-insult time to mammary tumor formation (CMO:0000345)599216724148607142Rat
7394708Emca11Estrogen-induced mammary cancer QTL 11mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)599753548113061097Rat
1578673Bmd13Bone mineral density QTL 134.9femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)5103689353148689353Rat

Markers in Region
D5Lev17  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.25103,991,975 - 103,992,098 (+)MAPPERmRatBN7.2
Rnor_6.05107,832,238 - 107,832,360NCBIRnor6.0
Rnor_5.05111,801,053 - 111,801,175UniSTSRnor5.0
RGSC_v3.45108,916,213 - 108,916,335UniSTSRGSC3.4
Celera5102,707,557 - 102,707,679UniSTS
Cytogenetic Map5q32UniSTS
PMC152255P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.25103,991,982 - 103,992,130 (+)MAPPERmRatBN7.2
Rnor_6.05107,832,245 - 107,832,392NCBIRnor6.0
Rnor_5.05111,801,060 - 111,801,207UniSTSRnor5.0
RGSC_v3.45108,916,220 - 108,916,367UniSTSRGSC3.4
Celera5102,707,564 - 102,707,711UniSTS
Cytogenetic Map5q32UniSTS


Related Rat Strains
The following Strains have been annotated to Cdkn2a


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium
Low 2 16 14 22 5
Below cutoff 19 14 14 5 14 2 3 7 5 13 6 2

Sequence

Nucleotide Sequences
RefSeq Transcripts NM_031550 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
GenBank Nucleotide AB081658 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AF474974 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AF474975 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AF474976 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AF474977 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY145882 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY679727 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  AY679728 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  CH473998 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ336094 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ336095 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ336096 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ350894 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ350895 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  DQ350896 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  JACYVU010000162 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
  L81167 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles

Reference Sequences
RefSeq Acc Id: ENSRNOT00000079251   ⟹   ENSRNOP00000072063
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl5103,984,949 - 104,003,149 (-)Ensembl
Rnor_6.0 Ensembl5107,823,374 - 107,841,175 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000084293   ⟹   ENSRNOP00000073038
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl5103,986,666 - 103,992,143 (-)Ensembl
Rnor_6.0 Ensembl5107,823,330 - 107,832,405 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000103638   ⟹   ENSRNOP00000087870
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl5103,984,956 - 103,992,143 (-)Ensembl
RefSeq Acc Id: NM_031550   ⟹   NP_113738
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.25103,984,949 - 103,992,143 (-)NCBI
Rnor_6.05107,823,323 - 107,832,405 (-)NCBI
Rnor_5.05111,556,970 - 111,557,193 (-)NCBI
Rnor_5.05111,793,603 - 111,801,220 (-)NCBI
RGSC_v3.45108,908,749 - 108,916,380 (-)RGD
Celera5102,700,552 - 102,707,724 (-)RGD
Sequence:
Reference Sequences
RefSeq Acc Id: NP_113738   ⟸   NM_031550
- UniProtKB: Q9R0Z3 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: ENSRNOP00000072063   ⟸   ENSRNOT00000079251
RefSeq Acc Id: ENSRNOP00000073038   ⟸   ENSRNOT00000084293
RefSeq Acc Id: ENSRNOP00000087870   ⟸   ENSRNOT00000103638

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q8QZZ9-F1-model_v2 AlphaFold Q8QZZ9 1-160 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13693832
Promoter ID:EPDNEW_R4357
Type:multiple initiation site
Name:Cdkn2a_2
Description:cyclin-dependent kinase inhibitor 2A
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_R4358  
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.05107,832,373 - 107,832,433EPDNEW
RGD ID:13693836
Promoter ID:EPDNEW_R4358
Type:multiple initiation site
Name:Cdkn2a_1
Description:cyclin-dependent kinase inhibitor 2A
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_R4357  
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.05107,841,191 - 107,841,251EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2323 AgrOrtholog
BioCyc Gene G2FUF-40776 BioCyc
Ensembl Genes ENSRNOG00000059837 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000072063.2 UniProtKB/TrEMBL
  ENSRNOP00000073038.2 UniProtKB/TrEMBL
  ENSRNOP00000087870 ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000079251.2 UniProtKB/TrEMBL
  ENSRNOT00000084293.2 UniProtKB/TrEMBL
  ENSRNOT00000103638 ENTREZGENE, UniProtKB/Swiss-Prot
Gene3D-CATH 1.25.40.20 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Ankyrin_rpt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ankyrin_rpt-contain_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tumor_suppres_ARF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:25163 UniProtKB/Swiss-Prot
NCBI Gene 25163 ENTREZGENE
Pfam Ank_4 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  P19Arf_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Cdkn2a PhenoGen
PROSITE ANK_REP_REGION UniProtKB/Swiss-Prot
SMART ANK UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF48403 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A0G2K211_RAT UniProtKB/TrEMBL
  A0A0G2K4G8_RAT UniProtKB/TrEMBL
  ARF_RAT UniProtKB/Swiss-Prot
  CDN2A_RAT UniProtKB/Swiss-Prot
  Q2I316_RAT UniProtKB/TrEMBL
  Q8CFC3_RAT UniProtKB/TrEMBL
  Q8QZZ9 ENTREZGENE
  Q9R0Z3 ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2005-10-11 Cdkn2a  cyclin-dependent kinase inhibitor 2A  p19ARF    Symbol and Name updated to reflect Human and Mouse nomenclature 1299863 APPROVED
2002-06-10 Cdkn2a  cyclin dependent kinase inhibitor 2A       Name updated 70585 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_disease may be inactivated via methylation in tumors induced by particulate carcinogens 1298567
gene_disease may be involved in Wallerian degeneration of central nervous system cells following injury 1298595
gene_disease allelic loss is associated with iron-mediated oxidative damage causing renal carcinogenesis 1298747
gene_disease inactivation in transformed cell lines and lung tumors is associated with aberrant methylation of CpG islands 1298748
gene_expression expressed in white matter astrocytes of CNS in developing embryo; expression is downregulated in normal adult CNS 1298595
gene_function inhibits CDK4 70441
gene_process functions as a tumor suppressor gene 1298747